FDA: 2×2×4 design; RSABE + ABE + σwT/σwR [Design Issues]

posted by Pharma_88 – India, 2020-03-13 09:14 (321 d 04:03 ago) – Posting: # 21262
Views: 1,732

» All of the product-specific guidances contain a section ‘Explanation’. See also Yu et al.


» » Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study?
» You can. Whether that is necessary in healthy volunteers depends on the drug.


» » Further, what is the BE limit for such drugs?
» It depends on \(\small{s_{wR}}\) observed in the study, i.e., reference-scaling is applied. Furthermore – irrespective of passing the scaled limits – the study has to pass 80.00–125.00% as well and the upper confidence limit of \(\small{\sigma_{wT}/\sigma_{wR}}\) has to be ≤2.5.

its common for all NTI or its varies from drug to drug?

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

 Admin contact
21,317 posts in 4,447 threads, 1,489 registered users;
online 15 (0 registered, 15 guests [including 6 identified bots]).
Forum time: Thursday 13:18 CET (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz